<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873531</url>
  </required_header>
  <id_info>
    <org_study_id>10-2021-12</org_study_id>
    <nct_id>NCT04873531</nct_id>
  </id_info>
  <brief_title>Feasibility of Neostigmine for Intraoperative Neuromonitoring in Thyroid Surgery</brief_title>
  <official_title>Feasibility of Neostigmine as a Reversal Agent of Neuromuscular Blockade for Intraoperative Neuromonitoring During Thyroid Surgery: a Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For successful intraoperative neuromonitoring (IONM), adequate reversal of neuromuscular&#xD;
      blocking agent is a prerequisite in thyroid surgery with .&#xD;
&#xD;
      The aim of this study is to investigate the feasibility of neostigmine just after tracheal&#xD;
      intubation on the IONM in thyroid surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For successful intraoperative neuromonitoring (IONM), adequate reversal of neuromuscular&#xD;
      blocking agent is a prerequisite in thyroid surgery with .&#xD;
&#xD;
      The aim of this study is to investigate the feasibility of neostigmine just after tracheal&#xD;
      intubation on the IONM in thyroid surgery.&#xD;
&#xD;
      This study will be performed as a randomized controlled trial with two groups (N group:&#xD;
      neostigmine group and NS group: normal saline group).&#xD;
&#xD;
      For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be&#xD;
      administered just after tracheal intubation.&#xD;
&#xD;
      For the NS group, normal saline with a same volume of the N group will be administered just&#xD;
      after tracheal intubation.&#xD;
&#xD;
      For all patients of two groups, investigators evaluate the quality of signal of IONM during&#xD;
      the surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 3, 2021</start_date>
  <completion_date type="Anticipated">May 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>For participant, they will be blind to the group which they will be assigned. The surgeon, who will evaluate the quality of the signal, will be blinded to patient's group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recovery of cricothyroid muscle twitching</measure>
    <time_frame>perioperative</time_frame>
    <description>Time from the rocuronium administration to recovery of cricothyroid muscle twitching</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>amplitude of EMG for V1</measure>
    <time_frame>During surgery</time_frame>
    <description>micro-volts (uV), Electromyography amplitude of the vagus nerve before tumor manipulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amplitude of EMG for R1</measure>
    <time_frame>During surgery</time_frame>
    <description>micro-volts (uV), Electromyography amplitude of the recurrent laryngeal nerve before tumor manipulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amplitude of EMG for R2</measure>
    <time_frame>During surgery</time_frame>
    <description>micro-volts (uV), Electromyography amplitude of the recurrent laryngeal nerve after tumor removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amplitude of EMG for V2</measure>
    <time_frame>During surgery</time_frame>
    <description>micro-volts (uV), Electromyography amplitude of the vagus nerve after tumor removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with involuntary movements disrupting surgery</measure>
    <time_frame>During surgery</time_frame>
    <description>number, number of patients who move involuntarily during surgery, which disrupt and pause the surgery to prevent harmful events, such as tracheal injuries by a sharp surgical devices during the surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Thyroid Diseases</condition>
  <condition>Surgical Injury</condition>
  <condition>Nerve Monitoring</condition>
  <arm_group>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the Neostigmine (N) group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.&#xD;
Investigators evaluate the quality of signal of IONM during the surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For the Normal saline (NS) group, normal saline with a same volume of the N group will be administered just after tracheal intubation.&#xD;
Investigators evaluate the quality of signal of IONM during the surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.&#xD;
Investigators evaluate the quality of signal of IONM during the surgery.</description>
    <arm_group_label>Neostigmine</arm_group_label>
    <other_name>N group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.&#xD;
Investigators evaluate the quality of signal of IONM during the surgery.</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>NS group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  open thyroid surgery with intraoperative neuromonitoring&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusal to participate in the study&#xD;
&#xD;
          -  rocuronium should not be used (e.g. renal dysfunction patient)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Man Lee, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung-Man Lee, MD.PhD</last_name>
    <phone>+82-2-870-2513</phone>
    <email>jungman007@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul Metropolitan Government Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung-Man Lee</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>thyroid surgery</keyword>
  <keyword>recurrent laryngeal nerve</keyword>
  <keyword>neostigmine</keyword>
  <keyword>intraoperative neuromonitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Intraoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>possible, If there would be reasonable explanation for sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

